NCT05722067

Brief Summary

GM508 CultActive is a bicarbonate buffered reagent and ready-to-use designed to investigate oocytes of patients with failed fertilization after previous Intracytoplasmatic Sperm Injection cycles. The investigators hypothesize that GM508 CultActive will improve the fertilization rate and embryo development of such IVF patients (a history of poor fertilization, a history of poor embryo quality, and over 40 years old expected challenging to conceive).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
68

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 20, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2023

Completed
1 month until next milestone

First Posted

Study publicly available on registry

February 10, 2023

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 23, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

March 20, 2026

Status Verified

March 1, 2026

Enrollment Period

2.2 years

First QC Date

November 20, 2022

Last Update Submit

March 18, 2026

Conditions

Keywords

artificial oocyte activationcalcium ionophoreivfpoor responder

Outcome Measures

Primary Outcomes (1)

  • fertilization rate

    The normal fertilization rate will defined as the number of zygotes with 2PN and 2PB per the total number of mature oocytes

    Day 1

Secondary Outcomes (3)

  • blastocyst formation rate

    Day 5

  • top-quality blastocyst formation rate

    Day 5

  • pregnancy outcome

    1 year

Study Arms (2)

oocytes treated with calcium ionophore

EXPERIMENTAL

Oocytes treated with a ready-to-use ionophore compound (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF). After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes subjected to AOA will transfer to the same time-lapse culture dish with the controlled sibling group.

Other: calcium ionophore

oocytes undergo routine IVF/ICSI protocol

NO INTERVENTION

Untreated control oocytes will immediately place into the time-lapse imaging system, and the culture protocol was routine.

Interventions

The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.

Also known as: GM508 CultActive
oocytes treated with calcium ionophore

Eligibility Criteria

Age20 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Low fertilization rate in previous IVF cycle (\<30%), or
  • Poor embryo developmental problems in previous IVF cycle, or
  • Diminished ovarian reserve (AMH\<1.2 or AFC\<5) and/or more than 40 y/o.

You may not qualify if:

  • Without or just one oocyte picked up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Chang Gung Memorial Hospital

Kaohsiung City, 123, Taiwan

Location

MeSH Terms

Conditions

InfertilityLong Qt Syndrome 3

Interventions

Calcium Ionophores

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

IonophoresMembrane Transport ModulatorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesSpecialty Uses of Chemicals

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 20, 2022

First Posted

February 10, 2023

Study Start

January 1, 2023

Primary Completion

March 23, 2025

Study Completion

June 30, 2025

Last Updated

March 20, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Locations